Go Deep
Innovent Biologics, Inc.
Innovent Biologics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,650 | 117.2 | 6.84 | 0.11 | 1,074.74 |
| Oct 2026 | 18,653 | 117.2 | 6.83 | 0.11 | 1,075.91 |
| Oct 2026 | 18,790 | 116.5 | 6.71 | 0.11 | 1,055.98 |
| Oct 2026 | 18,653 | 115.7 | 6.83 | 0.11 | 1,073.83 |
| Oct 2026 | 19,273 | 116.6 | 6.25 | 0.11 | 981.70 |
Innovent Biologics, Inc. Quarterly Results
Quarterly data isn't available for this company right now.
Innovent Biologics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 13,041,523,000.0 | 9,421,888,000.0 | 6,206,070,000.0 | 4,556,380,000.0 |
| Net Profit | 813,565,000.0 | -94,631,000.0 | -1,027,913,000.0 | -2,179,270,000.0 |
| EPS | 0.5 | -0.1 | -0.7 | -1.5 |
Innovent Biologics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 37,347,839,000.0 | 21,602,602,000.0 | 20,627,360,000.0 | 17,588,845,000.0 | — |
| Total Liabilities | 17,991,596,000.0 | 8,484,873,000.0 | 8,099,779,000.0 | 6,858,896,000.0 | — |
| Total Equity | 19,356,243,000.0 | 13,117,729,000.0 | 12,527,581,000.0 | 10,729,949,000.0 | — |
Owes vs Owns
Innovent Biologics, Inc. owed ¥0.48 for every ¥1 it owned in Dec 2025, up from ¥0.39 in Dec 2022.
| Period | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Owes vs Owns | 0.48× | 0.39× | 0.39× | 0.39× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Innovent Biologics, Inc. Assets & Liabilities Breakdown (CNY millions)
What it owns — Dec 2025
Cash & short-term investments 48.8%Receivables 4.6%Inventory 3.5%Fixed assets (tangible) 13.7%Intangible assets 5.0%Long-term investments 2.0%Other assets 22.3%
How it's funded — Dec 2025
Short-term debt 2.1%Long-term debt 5.3%Payables 1.3%Other liabilities 39.4%Shareholders' equity 51.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 18,231.4 | 7,883.7 | 10,119.8 | 8,264.6 |
| Receivables | 1,713.8 | 1,184.4 | 1,005.9 | 575.3 |
| Inventory | 1,301.7 | 822.2 | 968.1 | 1,428.9 |
| Fixed assets (tangible) | 5,120.3 | 5,439.4 | 4,576.3 | 4,060.7 |
| Intangible assets | 1,878.2 | 1,637.1 | 1,545.8 | 1,198.2 |
| Long-term investments | 762.2 | 859.0 | 0.0 | 630.2 |
| Other assets | 8,340.1 | 3,776.8 | 2,411.4 | 1,431.0 |
| Liabilities & equity | ||||
| Short-term debt | 789.2 | 405.1 | 1,195.2 | 888.0 |
| Long-term debt | 1,989.6 | 2,412.4 | 2,326.8 | 2,215.4 |
| Payables | 494.6 | 357.7 | 372.5 | 325.6 |
| Other liabilities | 14,718.2 | 5,309.7 | 4,205.3 | 3,429.8 |
| Shareholders' equity | 19,356.2 | 13,117.7 | 12,527.6 | 10,729.9 |
| Net tangible assets | 17,478.0 | 11,480.6 | 10,981.7 | 9,531.8 |
Innovent Biologics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | 10,001,012,000.0 | 1,287,024,000.0 | 147,810,000.0 | -1,918,804,000.0 |
| Investing Activities | -6,511,540,000.0 | -1,165,411,000.0 | -998,662,000.0 | -1,435,185,000.0 |
| Financing Activities | 4,728,470,000.0 | -606,632,000.0 | 2,587,257,000.0 | 2,892,082,000.0 |